

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



天津發展控股有限公司
TIANJIN DEVELOPMENT HOLDINGS LIMITED

(Incorporated in Hong Kong with limited liability)

(Stock Code: 882)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made by Tianjin Development Holdings Limited (the “**Company**”) pursuant to Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rules 13.09 and 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Tianjin Lisheng Pharmaceutical Co., Ltd. (天津力生製藥股份有限公司) (“**Lisheng Pharmaceutical**”), an indirect non-wholly owned subsidiary of the Company, has published an announcement on the website of Shenzhen Stock Exchange (www.szse.cn) in respect of its preliminary results for the year of 2017, full text of which is reproduced in the attachment of this announcement.

As at the date of this announcement, the Company indirectly holds approximately 34.41% of the issued share capital of Lisheng Pharmaceutical.

By Order of the Board
Tianjin Development Holdings Limited
Zeng Xiaoping
Chairman

Hong Kong, 28 February 2018

As at the date of this announcement, the Board of the Company consists of Mr. Zeng Xiaoping, Mr. Wang Zhiyong, Dr. Cui Di, Dr. Yang Chuan, Mr. Cheung Wing Yui, Edward, Dr. Chan Ching Har, Eliza*, Dr. Cheng Hon Kwan**, Mr. Mak Kwai Wing, Alexander**, Ms. Ng Yi Kum, Estella**, Mr. Wong Shiu Hoi, Peter** and Dr. Loke Yu**.*

* *non-executive director*

** *independent non-executive director*

TIANJIN LISHENG PHARMACEUTICAL CO., LTD.**PRELIMINARY RESULTS ANNOUNCEMENT FOR 2017**

The Company, our directors, supervisors and senior management warrant the truthfulness, accuracy and completeness of the contents of this announcement, and there are no false statements, misleading statements contained herein nor material omissions from this announcement.

CAUTION: The financial information for 2017 contained in this announcement is only the preliminary accounting data that has been reviewed by the internal audit department of the Company but has not been audited by the audit firm. There may be discrepancies between the information contained herein and the final data to be disclosed in the 2017 annual report. Investors are advised to beware of investment risks which may result therefrom.

1. KEY FINANCIAL INFORMATION AND INDICATORS FOR 2017

Unit: RMB

Item	The reporting period	For the same period of last year	Increase / (Decrease) (%)
Total revenue from operations	1,029,892,842.35	846,853,223.73	21.61
Profit from operations	132,541,260.98	131,285,327.96	0.96
Total profit	132,703,870.64	133,283,411.01	-0.43
Net profit attributable to the shareholders of the Company	116,013,939.31	115,606,305.74	0.35
Basic earnings per share (RMB)	0.64	0.63	1.59
Weighted average return on net assets	3.81%	3.87%	-0.06
	As at the end of the reporting period	As at the beginning of the reporting period	Increase / (Decrease) (%)
Total assets	3,659,964,426.39	3,485,746,657.15	5.00
Owners' equity attributable to the shareholders of the Company	3,081,599,672.76	3,015,150,238.94	2.20
Share capital	182,454,992.00	182,454,992.00	
Net assets per share attributable to the shareholders of the Company (RMB)	16.89	16.53	2.18

2. EXPLANATION OF OPERATING RESULTS AND FINANCIAL PERFORMANCE

During the reporting period, the increase in operating results and financial performance of the Company compared to last year was mainly due to the Company's overall solid operating performance by achieving sustainable growth of revenue from operations as well as delivering steady profitability levels as a result of continuous products promotion and market expansion.

3. EXPLANATION OF VARIANCES WITH THE PREVIOUS EXPECTED RESULTS DISCLOSURE

The operating results for 2017 were estimated in the 2017 Third Quarterly Report of the Company: the net profit attributable to shareholders of the Company ranged from 10% lower than to 20% higher than that of the same period of last year. There is no difference between the operating results disclosed in this announcement of the Company and the previous expected results disclosure.

4. DOCUMENTS AVAILABLE FOR INSPECTION

1. The comparative balance sheet and income statement signed and sealed by the legal representative of the Company, the head of accounting function and the head of accounting department;
2. Internal audit report signed by the head of internal audit department.

The Board of Directors of
Tianjin Lisheng Pharmaceutical Co., Ltd.
28 February 2018